Navigation Links
ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
Date:12/18/2007

LEXINGTON, Mass., Dec. 18 /PRNewswire/ -- ActivBiotics, Inc. today announced that following a review of strategic options after its clinical trial of Rifalazil failed in peripheral arterial disease patients, the Company is selling all or substantially all of its assets on an "as is" basis through an Assignment for the Benefit of Creditors, process. The Assignee of the assets is Mr. Joseph Finn, Jr., CPA (see contact details below). The bidding for the assets, which may be purchased separately or in combination, will begin today and end on February 1, 2008. Any person interested in purchasing the assets or learning more about the bidding process should contact the Assignee, Mr. Joseph Finn, Jr.

"The Board of Directors has decided to pursue the sale of the company's clinical and preclinical drug assets," said Steven C. Gilman, Ph.D., Chairman of ActivBiotics. "We believe that our anti-inflammatory Phase II drug candidate and our antibacterial library of compounds are of significant value to companies in those therapeutic areas," added Gilman. Bidding packages have been assembled and are ready to be distributed subject to a potential purchaser entering into a standard form confidentiality agreement.

The Company assets available for sale include:

1. A superoxide dismutase (SOD) mimetic program consisting of two clinical-stage drug candidates, M40403 and M40419, and a library of 250 small molecules which have potential as novel therapeutic agents for the treatment of inflammatory diseases. M40403, which has been studied in approximately 700 patients/subjects, has an active IND, and a protocol on file with the FDA under which a Phase II clinical trial for the treatment of post-operative ileus can be conducted, and a protocol to initiate a Phase II clinical trial for the treatment of oral mucositis. The Company has submitted and expects to shortly receive Orphan Drug Designation status in Europe and has an Orphan Drug application pending with th
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
2. Exelixis Sells 80% Stake in Artemis to Taconic
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
5. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
9. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... November 2012, the European Union (EU) mandated use of the ... PSUR – responding to the increasing need to understand and ... in many regions, the main objectives of the PBRER are ... analysis of new or emerging information on the risks of ... the potential benefits of a drug; and , ...
(Date:8/18/2014)... 19, 2014 2014 Deep Research ... a professional and in-depth research report on the ... information, including its definition, classification, application, and ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:8/18/2014)... , Aug. 18, 2014   Sterne, Kessler, Goldstein ... in Washington, DC , announced today ... Partes Review (IPR) with the U.S. Patent and ... subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR ... licensed by Myriad Genetics, Inc. These patents have been ...
(Date:8/18/2014)... 18, 2014 According to ... By Application (Municipal Wastewater Treatment and Industrial Wastewater ... Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), and ... MarketsandMarkets, The market for membrane bioreactor systems is ... at a CAGR of 15.28% between 2014 and ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... Jan. 3 Thoratec,Corporation (Nasdaq: THOR ), ... said today that it will be participating in ... Gary Burbach, president and chief executive officer, ... 8:30 a.m., Pacific Standard Time (11:30,a.m., Eastern Standard ...
... and CLAREMONT, Calif., Jan. 3 /Xinhua-PRNewswire-FirstCall/ --,Kiwa ... successful,exhibition of its Fertilizer Products in Dingxing, ... representatives with large volume distribution,businesses in 7 ... the exhibition,and agreements were reached with local ...
... 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical ... fibrotic and metabolic diseases, today announced the,appointment ... created position of,Chief Scientific Officer. Dr. Adorini ... research and development, recently serving as Chief ...
Cached Biology Technology:Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 3Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer 2
(Date:8/20/2014)... and POINT ROBERTS, Washington , August 20, ... Key Role in Addressing Security Concerns in the Payment Industry? ... news source covering leading sectors including biometrics, issues commentary from ... Jason Peaslee , Managing Partner at Thrive Analytics, ... Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ( ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... a virulent family of bacteria called Yersinia, a group ... These bacteria insert into their host cells proteins and ... things -- disrupting the cells' normal structure. One of ... Now, a study published by Rockefeller University researchers in ...
... tend to have a much lower quality of life when they ... in the latest issue of the UK-based Journal of Advanced Nursing. ... 1500g or less and compared them with a control group of ... when it came to physical, emotional, cognitive and social functions. , ...
... a little mean sometimes ?especially when there's a choice bit ... flies have shorter tempers than others. , Researchers in ... suite of genes that affect aggression in the fruit fly ... abnormal aggression in humans and other animals. , The ...
Cached Biology News:A wolf in sheep's clothing: Plague bacteria reveal one of their virulence tricks 2Very low birth weight linked to reduced quality of life in pre-school children 2Fruit fly aggression studies have relevance to humans, animals 2Fruit fly aggression studies have relevance to humans, animals 3
Request Info...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Biology Products: